Brochure
15 Apr 2021

Diacerein, Oral inhibition of interleukin-1 in the treatment of osteoarthritis

Download

DIACEREIN is indicated for the specific, long-term oral treatment of degenerative joint diseases (osteoarthritis and related diseases). DIACEREIN has a unique mode of action through inhibition of the production and activity of interleukin-1, the key mediator in the progression of osteoarthritis.

Content provided by our supplier

TRB Chemedica International SA

  • Country/Region:
    Switzerland
  • On CPHI since:
    2016
  • Certificates:
    2
  • Employees:
    500 - 999
Company types
Manufacturer/Innovator
View company profile

Other Content from TRB Chemedica International SA (2)